Plasma concentrations of endocannabinoids and related primary fatty acid amides in patients with post-traumatic stress disorder
Open accessAbstract
BACKGROUND: Endocannabinoids (ECs) and related N-acyl-ethanolamides (NAEs) play important roles in stress response regulation, anxiety and traumatic memories. In view of the evidence that circulating EC levels are elevated under acute mild stressful conditions in humans, we hypothesized that individuals with traumatic stress exposure and post-traumatic stress disorder (PTSD), an anxiety disorder characterized by the inappropriate persistence and uncontrolled retrieval of traumatic memories, show measurable alterations in plasma EC and NAE concentrations. METHODS: We determined plasma concentrations of the ECs anandamide (ANA) and 2-arachidonoylglycerol (2-AG) and the NAEs palmitoylethanolamide (PEA), oleoylethanolamide (OEA), stearoylethanolamine (SEA), and N-oleoyldopamine (OLDA) by HPLC-MS-MS in patients with PTSD (n = 10), trauma-exposed individuals without evidence of PTSD (n = 9) and in healthy control subjects (n = 29). PTSD was diagnosed according to DSM-IV criteria by administering the Clinician Administered PTSD Scale (CAPS), which also assesses traumatic events. RESULTS: Individuals with PTSD showed significantly higher plasma concentrations of ANA (0.48 ± 0.11 vs. 0.36 ± 0.14 ng/ml, p = 0.01), 2-AG (8.93 ± 3.20 vs. 6.26±2.10 ng/ml, p<0.01), OEA (5.90 ± 2.10 vs. 3.88 ± 1.85 ng/ml, p<0.01), SEA (2.70 ± 3.37 vs. 0.83 ± 0.47, ng/ml, p<0.05) and significantly lower plasma levels of OLDA (0.12 ± 0.05 vs. 0.45 ± 0.59 ng/ml, p<0.05) than healthy controls. Moreover, PTSD patients had higher 2-AG plasma levels (8.93 ± 3.20 vs. 6.01 ± 1.32 ng/ml, p = 0.03) and also higher plasma concentrations of PEA (4.06 ± 1.87 vs. 2.63±1.34 ng/ml, p<0.05) than trauma-exposed individuals without evidence of PTSD. CAPS scores in trauma-exposed individuals with and without PTSD (n = 19) correlated positively with PEA (r = 0.55, p = 0.02) and negatively with OLDA plasma levels (r = -0.68, p<0.01). CAPS subscores for intrusions (r = -0.65, p<0.01), avoidance (r = -0.60, p<0.01) and hyperarousal (r = -0.66, p<0.01) were all negatively related to OLDA plasma concentrations. CONCLUSIONS: PTSD appears to be associated with changes in plasma EC/NAE concentrations. This may have pathophysiological and diagnostic consequences but will need to be reproduced in larger cohorts.
AI snapshot
Written from the paper’s full text.
TL;DR
Plasma endocannabinoid and related N-acyl-ethanolamide concentrations differ between patients with PTSD, trauma-exposed individuals without PTSD, and healthy controls. The authors conclude PTSD may be associated with altered plasma EC/NAE levels, but findings require replication in larger cohorts.
Key findings
- PTSD patients had significantly higher plasma ANA (0.48±0.11 vs. 0.36±0.14 ng/ml, p=0.01), 2-AG (8.93±3.20 vs. 6.26±2.10 ng/ml, p<0.01), OEA (5.90±2.10 vs. 3.88±1.85 ng/ml, p<0.01), and SEA (2.70±3.37 vs. 0.83±0.47 ng/ml, p<0.05), and significantly lower OLDA (0.12±0.05 vs. 0.45±0.59 ng/ml, p<0.05) than healthy controls.
- PTSD patients also had higher 2-AG (8.93±3.20 vs. 6.01±1.32 ng/ml, p=0.03) and PEA (4.06±1.87 vs. 2.63±1.34 ng/ml, p<0.05) than trauma-exposed individuals without PTSD.
- In trauma-exposed individuals with and without PTSD (n=19), CAPS scores correlated positively with PEA (r=0.55, p=0.02) and negatively with OLDA (r=−0.68, p<0.01); CAPS subscores for intrusions (r=−0.65), avoidance (r=−0.60), and hyperarousal (r=−0.66) were negatively related to OLDA.
- Plasma cortisol did not differ significantly between groups (14.0±7.0 µg/dl in trauma-exposed without PTSD, 10.2±7.02 µg/dl in PTSD, 11.2±6.53 µg/dl in controls; p=0.45).
Methods
- Case-control study comparing patients with PTSD (n=10), trauma-exposed individuals without PTSD (n=9), and healthy controls (n=29); PTSD was diagnosed by DSM-IV criteria using the Clinician Administered PTSD Scale (CAPS).
- Plasma concentrations of ANA, 2-AG, PEA, OEA, SEA, and OLDA were measured by HPLC-MS-MS; cortisol was measured by automated electrochemiluminescence immunoassay.
- Group comparisons used ANOVA or Kruskal-Wallis ANOVA on Ranks with post-hoc tests; relationships between continuous variables used Pearson’s r or Spearman’s ρ.
Limitations
- The paper states that findings need to be reproduced in larger and more homogeneous cohorts, and that interpretation is hampered by limited knowledge of the biological effects and regulation of many measured ECs/NAEs.
- The paper notes that peripheral plasma concentrations were measured although most stress/memory effects of lipid signaling are central, and that ethnic differences within the subject pool required exploratory subanalyses.
- Evident from the text: group sizes were small (PTSD n=10, trauma-exposed without PTSD n=9), multiple secondary and subgroup analyses were performed, and the cross-sectional design cannot establish whether EC/NAE changes are causal, protective, or consequential in PTSD.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 48 cited sources checked · 0 supported · 0 flagged
- Findingown data
Individuals with PTSD had significantly higher plasma concentrations of oleoylethanolamide (OEA) than healthy controls (5.90±2.10 vs. 3.88±1.85 ng/ml, p<0.01).
“OEA (5.90±2.10 vs. 3.88±1.85 ng/ml, p<0.01)”
- Also stated in: § Endocannabinoid Plasma Concentrations · plain
“OEA (5.90±2.10 vs. 3.88±1.85 ng/ml, p<0.01)”
Quote in the paperSubstantial claim - Also stated in: § Endocannabinoid Plasma Concentrations · plain
- Findingown data
CAPS subscores for hyperarousal were negatively related to OLDA plasma concentrations (r=−0.66, p<0.01).
“CAPS subscores for intrusions (r = −0.65, p<0.01), avoidance (r = −0.60, p<0.01) and hyperarousal (r = −0.66, p<0.01) were all negatively related to OLDA plasma concentrations.”
Quote in the paperNot a substantial claim - Findingown data
No signals of native DEA, DLE or NADA could be found in trauma-exposed subjects or controls.
“Isotope-labeled DEA, DLE and NADA could be readily detected in the samples but no signals of native DEA, DLE or NADA could be found in trauma-exposed subjects or controls.”
Quote in the paperNot a substantial claim - Findingown data
CAPS scores in trauma-exposed individuals with and without PTSD (n=19) correlated positively with PEA plasma levels (r=0.55, p=0.02).
“CAPS scores in trauma-exposed individuals with and without PTSD (n = 19) correlated positively with PEA (r = 0.55, p = 0.02) and negatively with OLDA plasma levels (r = −0.68, p<0.01).”
Quote in the paperSubstantial claim - Findingown data
PTSD patients had higher plasma 2-AG concentrations than trauma-exposed individuals without evidence of PTSD (8.93±3.20 vs. 6.01±1.32 ng/ml, p=0.03).
“Moreover, PTSD patients had higher 2-AG (8.93±3.20 vs. 6.01±1.32 ng/ml, p = 0.03) and PEA plasma levels (4.06±1.87 vs. 2.63±1.34 ng/ml, p<0.05) than trauma-exposed individuals without evidence of PTSD (Figure 1).”
Quote in the paperSubstantial claim
- Findingown data
Individuals with PTSD had significantly higher plasma concentrations of anandamide (ANA) than healthy controls (0.48±0.11 vs. 0.36±0.14 ng/ml, p=0.01).
“Individuals with PTSD showed significantly higher plasma concentrations of ANA (0.48±0.11 vs. 0.36±0.14 ng/ml, p = 0.01)”
- Also stated in: § Endocannabinoid Plasma Concentrations · plain
“Traumatized subjects with PTSD showed significantly higher plasma concentrations of ANA (0.48±0.11 vs. 0.36±0.14 ng/ml, p = 0.01)”
Quote in the paperSubstantial claim - Also stated in: § Endocannabinoid Plasma Concentrations · plain
- Findingown data
Individuals with PTSD had significantly higher plasma concentrations of 2-arachidonoylglycerol (2-AG) than healthy controls (8.93±3.20 vs. 6.26±2.10 ng/ml, p<0.01).
“2-AG (8.93±3.20 vs. 6.26±2.10 ng/ml, p<0.01)”
- Also stated in: § Endocannabinoid Plasma Concentrations · plain
“2-AG (8.93±3.20 vs. 6.26±2.10 ng/ml, p<0.01)”
Quote in the paperSubstantial claim - Also stated in: § Endocannabinoid Plasma Concentrations · plain
- Findingown data
CAPS subscores for intrusions were negatively related to OLDA plasma concentrations (r=−0.65, p<0.01).
“CAPS subscores for intrusions (r = −0.65, p<0.01), avoidance (r = −0.60, p<0.01) and hyperarousal (r = −0.66, p<0.01) were all negatively related to OLDA plasma concentrations.”
Quote in the paperSubstantial claim - Findingown data
Individuals with PTSD had significantly lower plasma concentrations of N-oleoyldopamine (OLDA) than healthy controls (0.12±0.05 vs. 0.45±0.59 ng/ml, p<0.05).
“significantly lower plasma levels of OLDA (0.12±0.05 vs. 0.45±0.59 ng/ml, p<0.05) than healthy controls”
- Also stated in: § Endocannabinoid Plasma Concentrations · plain
“significantly lower plasma levels of OLDA (0.12±0.05 vs. 0.45±0.59 ng/ml, p<0.05) than healthy controls”
Quote in the paperSubstantial claim - Also stated in: § Endocannabinoid Plasma Concentrations · plain
- Findingown data
Average CAPS scores were 94.9±15.4 for trauma-exposed subjects with PTSD and 24.6±24.4 for trauma-exposed subjects without PTSD (p<0.01).
“Average CAPS scores were 94.9±15.4 for the trauma-exposed subjects with PTSD and 24.6±24.4 for trauma-exposed subjects without PTSD (p<0.01, Table 1).”
Quote in the paperNot a substantial claim - Findingown data
No significant effect of depression or antidepressant use on plasma EC/NAE levels was found in the secondary analysis.
“We found no significant effect of depression or antidepressants on plasma EC/NAE levels (Table 2).”
Quote in the paperSubstantial claim - Findingown data
CAPS subscores for avoidance were negatively related to OLDA plasma concentrations (r=−0.60, p<0.01).
“CAPS subscores for intrusions (r = −0.65, p<0.01), avoidance (r = −0.60, p<0.01) and hyperarousal (r = −0.66, p<0.01) were all negatively related to OLDA plasma concentrations.”
Quote in the paperSubstantial claim - Findingown data
Individuals with PTSD had significantly higher plasma concentrations of stearoylethanolamine (SEA) than healthy controls (2.70±3.37 vs. 0.83±0.47 ng/ml, p<0.05).
“SEA (2.70±3.37 vs. 0.83±0.47, ng/ml, p<0.05)”
- Also stated in: § Endocannabinoid Plasma Concentrations · plain
“SEA (2.70±3.37 vs. 0.83±0.47, ng/ml, p<0.05)”
Quote in the paperSubstantial claim - Also stated in: § Endocannabinoid Plasma Concentrations · plain
- Findingown data
PTSD patients had higher plasma PEA concentrations than trauma-exposed individuals without evidence of PTSD (4.06±1.87 vs. 2.63±1.34 ng/ml, p<0.05).
“Moreover, PTSD patients had higher 2-AG (8.93±3.20 vs. 6.01±1.32 ng/ml, p = 0.03) and PEA plasma levels (4.06±1.87 vs. 2.63±1.34 ng/ml, p<0.05) than trauma-exposed individuals without evidence of PTSD (Figure 1).”
Quote in the paperSubstantial claim - Findingown data
Trauma-exposed individuals with somatic comorbidities or medication use (except antidepressants) had nearly identical plasma levels of ECs/NAEs compared to those without such comorbidities or medication use.
“Trauma-exposed individuals who reported somatic comorbidities (n = 4) or the use of any type of medication except antidepressives (n = 5), had nearly identical plasma levels of ECs or NAEs compared to participants without any comorbidities or medication use (Table 3).”
Quote in the paperNot a substantial claim - Findingown data
CAPS scores in trauma-exposed individuals with and without PTSD (n=19) correlated negatively with OLDA plasma levels (r=−0.68, p<0.01).
“CAPS scores in trauma-exposed individuals with and without PTSD (n = 19) correlated positively with PEA (r = 0.55, p = 0.02) and negatively with OLDA plasma levels (r = −0.68, p<0.01).”
Quote in the paperSubstantial claim - Findingown data
Within the trauma-exposed group (n = 19), CAPS sum score correlated positively with PEA plasma levels.
“Within the trauma-exposed group (n = 19) the CAPS sum score and the intrusion subscore correlated positively with PEA plasma levels (Figure 3).”
- Also stated in: § Endocannabinoid Plasma Concentrations · plain
“Panel A: CAPS sum score (r = 0.54, p = 0.02);”
Quote in the paperNot a substantial claim - Also stated in: § Endocannabinoid Plasma Concentrations · plain
- Findingown data
In a subanalysis excluding German subjects from the control group, individuals with PTSD showed significantly lower OLDA concentrations than controls.
“as well as significantly lower OLDA concentrations (0.12±0.05 vs. 0.19±0.08 ng/ml, p = 0.007).”
Quote in the paperSubstantial claim - Findingown data
There were no significant correlations between the other ECs/NAEs measured and traumatic event types.
“with no significant correlations between the other ECs/NAEs measured and traumatic event types (data not shown).”
Quote in the paperNot a substantial claim - Findingown data
In a subanalysis excluding German subjects from the control group, individuals with PTSD showed significantly higher 2-AG concentrations than the ethnically more comparable controls (n = 9).
“In this subanalysis, individuals with PTSD showed still significantly higher 2-AG concentrations as compared to the ethnically more comparable controls (n = 9) (8.93±3.16 vs. 5.71±2.90 ng/ml, p = 0.02, ANOVA with Holm-Sidak post-hoc test)”
Quote in the paperSubstantial claim - Findingown data
There was a negative correlation between the number of reported CAPS traumatic event types and OLDA plasma levels.
“Furthermore, there was a negative correlation between the number of reported CAPS traumatic events types and OLDA plasma levels (Figure 5)”
- Also stated in: § Endocannabinoid Plasma Concentrations · plain
“Figure 5 Correlation between the number of CAPS traumatic event types and OLDA plasma concentrations (r = −0.50, p = 0.03, n = 19).”
Quote in the paperNot a substantial claim - Also stated in: § Endocannabinoid Plasma Concentrations · plain
- Findingown data
Within the trauma-exposed group (n = 19), all CAPS subscores correlated negatively with OLDA concentrations.
“OLDA plasma levels were negatively related to the CAPS sum score, and all CAPS subscores correlated negatively with OLDA concentrations (Figure 4).”
- Also stated in: § Endocannabinoid Plasma Concentrations · plain
“Panel B: CAPS – intrusion subscore (r = −0.65, p<0.01); Panel C: CAPS – avoidance subscore (r = −0.59, p<0.01); Panel D: CAPS – hyperarousal subscore (r = −0.66, p<0.01).”
Quote in the paperNot a substantial claim - Also stated in: § Endocannabinoid Plasma Concentrations · plain
- Findingown data
Within the trauma-exposed group (n = 19), CAPS intrusion subscore correlated positively with PEA plasma levels.
“Within the trauma-exposed group (n = 19) the CAPS sum score and the intrusion subscore correlated positively with PEA plasma levels (Figure 3).”
- Also stated in: § Endocannabinoid Plasma Concentrations · plain
“Panel B: CAPS – intrusion subscore (r = 0.65, p<0.01);”
Quote in the paperNot a substantial claim - Also stated in: § Endocannabinoid Plasma Concentrations · plain
- Findingown data
Within the trauma-exposed group (n = 19), OLDA plasma levels were negatively related to the CAPS sum score.
“OLDA plasma levels were negatively related to the CAPS sum score, and all CAPS subscores correlated negatively with OLDA concentrations (Figure 4).”
- Also stated in: § Endocannabinoid Plasma Concentrations · plain
“Panel A: CAPS sum score (r = −0.68, p<0.01, n = 19);”
Quote in the paperNot a substantial claim - Also stated in: § Endocannabinoid Plasma Concentrations · plain
- Findingown data
When non-Caucasian individuals were excluded from analysis, differences in ANA, SEA and OEA between PTSD patients and controls remained significant.
“When non-Caucasians were excluded, differences in ANA, SEA and OEA in individuals with PTSD in relation to controls remained significant.”
- Also stated in: § Discussion · plain
“When individuals of African origin were excluded, ANA, SEA and OEA remained significantly elevated;”
Quote in the paperSubstantial claim - Also stated in: § Discussion · plain
- Findingown data
Smokers tended to exhibit higher EC/NAE plasma concentrations.
“and that smokers tended to exhibit higher EC/NAE plasma concentrations”
Quote in the paperNot a substantial claim - Findingown data
With the exception of SAE, there was no correlation between cortisol values and EC/NAE levels.
“With the exception of a negative relationship between SAE plasma concentrations and cortisol levels in traumatized individuals (r = −0.55, p = 0.02, n = 19), we found no correlation between cortisol values and EC/NAE levels.”
Quote in the paperNot a substantial claim - Findingown data
There was no significant correlation between the number of CAPS traumatic event types experienced, CAPS, SOMS, and HAMD scores, and plasma cortisol values.
“There was also no significant correlation between the number of CAPS traumatic event types experienced, CAPS, SOMS, and HAMD scores, and plasma cortisol values.”
Quote in the paperNot a substantial claim - Findingown data
The number of cigarettes/day smoked by traumatized individuals in the study correlated with CAPS summary scores.
“This assumption is corroborated by the observation that the number of cigarettes/day smoked by traumatized individuals in our study correlated with CAPS summary scores”
Quote in the paperNot a substantial claim - Findingown data
Plasma concentrations of ECs and NAEs in trauma-exposed individuals who did not develop PTSD were often between those of controls and those of subjects with the full syndrome of PTSD.
“It is of interest to note that plasma concentrations of ECs and NAEs in trauma-exposed individuals who did not develop PTSD were often between those of controls and those of subjects with the full syndrome of PTSD.”
Quote in the paperSubstantial claim - Findingown data
There are significant correlations between CAPS scores and plasma concentrations of the NAEs PEA and OLDA in stressed, trauma-exposed individuals.
“Furthermore, we found significant correlations between CAPS scores and plasma concentrations of the NAEs PEA and OLDA in stressed, trauma-exposed individuals.”
Quote in the paperSubstantial claim - Findingown data
There was a negative relationship between SAE plasma concentrations and cortisol levels in traumatized individuals (r = −0.55, p = 0.02, n = 19).
“With the exception of a negative relationship between SAE plasma concentrations and cortisol levels in traumatized individuals (r = −0.55, p = 0.02, n = 19), we found no correlation between cortisol values and EC/NAE levels.”
Quote in the paperNot a substantial claim - Findingown data
Cortisol concentrations did not differ significantly between trauma-exposed individuals without PTSD, PTSD patients, and controls (p = 0.45).
“Cortisol concentrations in trauma-exposed individuals without PTSD were 14.0±7.0 µg/dl, 10.2±7.02 µg/dl in PTSD patients and 11.2±6.53 µg/dl in controls, but the difference between groups was not statistically significant (p = 0.45).”
Quote in the paperNot a substantial claim - Findingown data
Individuals who developed PTSD had experienced a significantly higher number of war and torture events than traumatized subjects without PTSD.
“Individuals who developed PTSD had experienced a significantly higher number of war and torture events than traumatized subjects without PTSD”
Quote in the paperSubstantial claim - Findingown data
There was no direct correlation between EC/NAE concentration and the amount of daily tobacco consumption.
“albeit without a direct correlation between EC/NAE concentration and the amount of daily tobacco consumption.”
Quote in the paperNot a substantial claim - Premisecitation
Elevated EC signaling during stress regulates the extinction of traumatic memories.
“As part of this protective role under aversive conditions, elevated EC signaling during stress has been shown to dampen the development of anxiety [12] and to regulate the encoding [13], retrieval [14] and extinction [15] of traumatic memories.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [15] G Marsicano, 2002, The endogenous cannabinoid system controls extinction of aversive memories, Nature source
Not checked in the free run.
- Premisecitation
Elevated EC signaling during stress regulates the encoding of traumatic memories.
“As part of this protective role under aversive conditions, elevated EC signaling during stress has been shown to dampen the development of anxiety [12] and to regulate the encoding [13], retrieval [14] and extinction [15] of traumatic memories.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [13] P Campolongo, 2009, Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory, Proc Natl Acad Sci U S A source
Not checked in the free run.
- Premisecitation
Elevated EC signaling during stress regulates the retrieval of traumatic memories.
“As part of this protective role under aversive conditions, elevated EC signaling during stress has been shown to dampen the development of anxiety [12] and to regulate the encoding [13], retrieval [14] and extinction [15] of traumatic memories.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [14] P Atsak, 2012, Glucocorticoids interact with the hippocamapal endocannabinoid system in impairing retrieval of contextual fear memory, Proc Natl Acad Sci U S A source
Not checked in the free run.
- Study design and conductcitation
PTSD was excluded in control subjects by using the Post-Traumatic Stress Symptom 10 Questionnaire (PTSS-10).
“PTSD was excluded in these individuals by using the Post-Traumatic Stress Symptom 10 Questionnaire (PTSS-10) [27].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [27] C Stoll, 1999, Sensitivity and specificity of a screening test to document traumatic experiences and to diagnose post-traumatic stress disorder in ARDS patients after intensive care treatment, Intensive Care Med source
Not checked in the free run.
- Premisecitation
Elevated EC signaling during stress dampens the development of anxiety.
“As part of this protective role under aversive conditions, elevated EC signaling during stress has been shown to dampen the development of anxiety [12] and to regulate the encoding [13], retrieval [14] and extinction [15] of traumatic memories.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [12] FA Moreira, 2010, Cannabinoids and anxiety, Current Topics in Behavioral Neurosciences source
Not checked in the free run.
- Premisecitation
Recent studies in animals and humans point to a major role of EC signaling in both the periphery and central nervous system in controlling adaptive processes to aversive situations and regulating and limiting stress reactions.
“Despite the abovementioned diversity in central and peripheral functions, recent studies in animals [9] and humans [10] point to a major role of EC signaling in both the periphery [10] and central nervous system [11] in controlling adaptive processes to aversive situations and regulating and limiting stress reactions.”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [9] S Patel, 2008, Adaptations in endocannabinoid signaling in response to repeated homotypic stress: a novel mechanism for stress habituation, Eur J Neurosci source
Not checked in the free run.
- cites [10] A Chouker, 2010, Motion sickness, stress and the endocannabinoid system, PLoS One source
Not checked in the free run.
- cites [11] MN Hill, 2010, Endogenous cannabinoid signaling is essential for stress adaptation, Proc Natl Acad Sci U S A source
Not checked in the free run.
- Premisecitation
A pilot study by the authors in critically ill patients awaiting cardiac surgery indicated increased plasma concentrations of ANA and 2-AG in stressed patients with traumatic experiences and PTSD symptoms as a result of heart disease.
“Furthermore, a pilot study by our group in critically ill patients (n = 90) awaiting cardiac surgery indicated increased plasma concentrations of ANA and 2-AG in stressed patients with traumatic experiences and PTSD symptoms as a result of heart disease [19].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [19] D Hauer, 2008, Traumatic Memories in Surgical Patients Are a Significant Predictor of Endocannabinoid Activity, Anesthesiology
Not checked in the free run.
- Interpretationown data
PTSD appears to be associated with changes in plasma EC/NAE concentrations.
“PTSD appears to be associated with changes in plasma EC/NAE concentrations.”
Quote in the paperSubstantial claim - Interpretationown data
PTSD is associated with changes in the pattern of plasma EC/NAE concentrations.
“Despite these limitations, our findings indicate that PTSD is associated with changes in the pattern of plasma EC/NAE concentrations.”
Quote in the paperSubstantial claim - Interpretationown data
The loss of significance in ANA, SEA and OEA in the subanalysis excluding German controls was due to increased EC/NAE levels in the remaining controls.
“Beside the lower statistical power due to the smaller control group, the loss of significance in ANA, SEA and OEA was due to increased EC/NAE levels in the remaining controls.”
Quote in the paperNot a substantial claim- Rests on an assumption: The remaining controls (refugees) were exposed to higher stress levels during immigration, which could result in increased plasma lipid signaling.
- Interpretationown data
The intermediate levels of ECs/NAEs in trauma-exposed individuals without PTSD suggest stress-dose dependent changes in lipid signaling.
“This suggests stress-dose dependent changes in lipid signaling which is also corroborated by our observation that CAPS and CAPS subscores correlated with EC/NAE plasma levels.”
Quote in the paperSubstantial claim - Premisecitation
Patients undergoing cardiac surgery who showed an impaired EC response during the stressful postoperative period were at an increased risk for depression at 6 months after surgery.
“Likewise, patients undergoing cardiac surgery who showed an impaired EC response during the stressful postoperative period were at an increased risk for depression at 6 months after surgery [39].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [39] D Hauer, 2012, Glucocorticoid-endocannabinoid interaction in cardiac surgical patients: relationship to early cognitive dysfunction and late depression, Rev Neurosci source
Not checked in the free run.
- Premisecitation
Use of the synthetic cannabinoid nabilone resulted in an improvement of symptoms.
“and the use of the synthetic cannabinoid nabilone resulted in an improvement of symptoms [17].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [17] GA Fraser, 2009, The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD), CNS neuroscience & therapeutics source
Not checked in the free run.
- Premisecitation
Patients with major depression show reduced serum ANA and 2-AG concentrations.
“The possible protective effects of an activated EC system are illustrated by the fact that patients with major depression show reduced serum ANA and 2-AG concentrations [7]”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [7] MN Hill, 2009, Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress, Psychoneuroendocrinology source
Not checked in the free run.
- Premisecitation
Use of the CB1 receptor antagonist rimonabant as an anti-obesity drug has been associated with a significant increase in the risk for depression.
“and that the use of the CB1 receptor antagonist rimonabant as an anti-obesity drug has been associated with a significant increase in the risk for depression.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [5] JP Despres, 2005, Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia, N Engl J Med source
Not checked in the free run.
- Premisecitation
Animal experiments showed that systemic and intracranial injection of cannabinoids, resulting in an increase in EC signaling, prevented the effects of intense stress in animal models of PTSD.
“In line with this assumption, animal experiments showed that the systemic and intracranial injection of cannabinoids, resulting in an increase in EC signaling, prevented the effects of intense stress in animal models of PTSD [40].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [40] E Ganon-Elazar, 2012, Cannabinoids prevent the development of behavioral and endocrine alterations in a rat model of intense stress, Neuropsychopharmacology source
Not checked in the free run.
- Premisecitation
Systemic administration of OEA to rats, resulting in elevated OEA plasma levels as seen in PTSD patients, improved memory of aversive training experiences.
“The systemic administration of OEA to rats, resulting in elevated OEA plasma levels as seen in our PTSD patients, improved memory of aversive training experiences [46].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [46] P Campolongo, 2009, Fat-induced satiety factor oleoylethanolamide enhances memory consolidation, Proc Natl Acad Sci U S A source
Not checked in the free run.
- Premisecitation
The stress of footshock delivery to rats resulted in an almost simultaneous increase in ANA concentrations in blood and several memory-related brain areas including the amygdala and hippocampus.
“The stress of footshock delivery to rats resulted in an almost simultaneous increase in ANA concentrations in blood and several memory–related brain areas including the amygdala and hippocampus (Hauer D., Campolongo P. et al., in preparation).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Hauer D., Campolongo P. et al., in preparation
Not checked in the free run.
- Interpretationreasoning
Chronic elevation of EC and NAE levels in traumatized individuals could result in desensibilisation or downregulation of one or more receptor types for ECs or NAEs.
“A likely explanation for this phenomenon is that the chronic elevation of EC and NAE levels in traumatized individuals could result in a desensibilisation or downregulation of one or more receptor types for ECs or NAEs.”
Quote in the paperSubstantial claim - Premisecitation
ECs and related compounds are able to cross the blood-brain barrier.
“There is, however, evidence that ECs and related compounds are able to cross the blood-brain barrier [45].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [45] ST Glaser, 2006, Ex vivo imaging of fatty acid amide hydrolase activity and its inhibition in the mouse brain, J Pharmacol Exp Ther source
Not checked in the free run.
- Premisecitation
Most effects of lipid signaling molecules on stress and memory are central.
“Other limitations of our study result from the fact that we measured peripheral plasma concentrations of ECs/NAEs whereas most effects of lipid signaling molecules on stress and memory are central [13]–[15], [44].”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [13]–[15]
Not checked in the free run.
- cites [44] MN Hill, 2009, Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis, Neuropsychopharmacology source
Not checked in the free run.
- Classified as probably not a substantial claim. 40
- May combine two claims. 23
Probably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataEight of the trauma-exposed individuals met DSM-IV criteria for a current major depressive episode.
“Eight of the trauma-exposed individuals met the DSM-IV criteria for a current major depressive episode (two subjects from the trauma exposure only group and six individuals with PTSD, p = 0.15, Fisher’s exact test) and two subjects from the PTSD group fulfilled DSM-IV criteria for alcohol dependency.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataIn traumatized individuals, the number of cigarettes smoked/day correlated with CAPS sum scores (r=0.505, p=0.006).
“In traumatized individuals, the number of cigarettes smoked/day correlated with CAPS sum scores (r = 0.505, p = 0.006).”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataPTSD symptoms in patients with PTSD were present between 6 and 204 months.
“PTSD symptoms in patients with PTSD were present between 6 and 204 months and all patients except one had experienced the traumatic events during early or late adulthood.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataCAPS scores correlated positively with the number of traumatic event types experienced (r=0.70, p<0.01).
“As expected, CAPS, HAMD and SOMS scores correlated positively with the number of traumatic event types experienced (CAPS: r = 0.70, p<0.01; HAMD: r = 0.71, p<0.01; SOMS: r = 0.55, p<0.01).”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataAll patients with PTSD except one had experienced the traumatic events during early or late adulthood.
“PTSD symptoms in patients with PTSD were present between 6 and 204 months and all patients except one had experienced the traumatic events during early or late adulthood.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataTwo subjects from the PTSD group fulfilled DSM-IV criteria for alcohol dependency.
“Eight of the trauma-exposed individuals met the DSM-IV criteria for a current major depressive episode (two subjects from the trauma exposure only group and six individuals with PTSD, p = 0.15, Fisher’s exact test) and two subjects from the PTSD group fulfilled DSM-IV criteria for alcohol dependency.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataSOMS scores correlated positively with the number of traumatic event types experienced (r=0.55, p<0.01).
“As expected, CAPS, HAMD and SOMS scores correlated positively with the number of traumatic event types experienced (CAPS: r = 0.70, p<0.01; HAMD: r = 0.71, p<0.01; SOMS: r = 0.55, p<0.01).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataStudy participants including healthy controls who smoked tended to have higher EC/NAE concentrations than non-smokers, but the differences were not statistically significant.
“Study participants including healthy controls who smoked (n = 11) tended to have higher EC/NAE concentrations than non-smokers (n = 37) but these differences were not statistically significant (Table 4).”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataHAMD scores correlated positively with the number of traumatic event types experienced (r=0.71, p<0.01).
“As expected, CAPS, HAMD and SOMS scores correlated positively with the number of traumatic event types experienced (CAPS: r = 0.70, p<0.01; HAMD: r = 0.71, p<0.01; SOMS: r = 0.55, p<0.01).”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataNo statistically significant correlation was found between plasma concentration of EC/NAE compounds and the number of cigarettes smoked/day, neither in the whole study group nor when only trauma-exposed individuals with and without PTSD were included.
“We found no statistically significant correlation between plasma concentration of EC/NAE compounds and the number of cigarettes smoked/day, neither in the whole study group (r≤0.155, p≥0.29, n = 48) nor when only trauma-exposed individuals with and without PTSD were included in the analyses (r≤0.312, p≥0.080, n = 19).”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataFour of the trauma-exposed individuals reported chronic somatic disorders.
“Four of the trauma-exposed individuals reported chronic somatic disorders (two had recent treatment for stomach ulcerations, one had a rheumatic disorder, and one was diagnosed as hepatitis B-positive).”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataTwelve subjects were cigarette smokers.
“Twelve subjects were cigarette smokers.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataSeven of the 19 trauma-exposed individuals reported current intake of anxiolytic, antidepressant, neuroleptic or contraceptive medication.
“Seven of the 19 trauma-exposed individuals reported current intake of anxiolytic, antidepressant, neuroleptic or contraceptive medication.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataWhen non-Caucasian individuals were excluded from analysis, OLDA levels remained lower in PTSD patients but significance was lost after correction for multiple comparisons.
“OLDA levels remained also significantly lower but significance was lost after correction for multiple comparisons.”
- Also stated in: § Endocannabinoid Plasma Concentrations · plain
“Panel F: OLDA concentrations across the 3 study subgroups (Kruskal-Wallis ANOVA on Ranks indicated a significant difference among the groups (+p = 0.02) but significance was lost after correction for multiple comparisons (diff. of ranks 11.7, Q = 2.23, p>0.05).”
Quote in the paperNot a substantial claim- Also stated in: § Endocannabinoid Plasma Concentrations · plain
May combine two claims.
Findingown dataWhen non-Caucasian individuals were excluded from analysis, 2-AG and PEA levels were still elevated in PTSD patients but differences to healthy controls were no longer significant.
“2-AG and PEA levels were still elevated in PTSD patients but the differences to healthy controls were no longer significant (Figure 2).”
- Also stated in: § Endocannabinoid Plasma Concentrations · plain
“The differences between groups shown in Panel B (2-AG) and Panel E (PEA) were not statistically significant in the subanalysis.”
Quote in the paperSubstantial claim- Also stated in: § Endocannabinoid Plasma Concentrations · plain
May combine two claims.
Findingown dataIndividuals with PTSD show significant differences in plasma concentrations of ECs and NAEs when compared to healthy controls and to subjects after trauma exposure who did not develop PTSD.
“Our findings indicate that individuals with PTSD show significant differences in plasma concentrations of ECs and NAEs when compared to healthy controls and to subjects after trauma exposure who did not develop PTSD.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataSecondary analyses showed no differences in EC/NAE plasma concentrations in traumatized individuals on antidepressants and between depressed and non-depressed individuals.
“Moreover, our secondary analyses showed no differences in EC/NAE plasma concentrations in traumatized individuals on antidepressants and between depressed and non-depressed individuals.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataWhen only refugees with presumed differences in stress exposure were compared, only 2-AG levels remained significantly higher and OLDA concentrations significantly lower.
“When only refugees with presumed differences in stress exposure were compared, only 2-AG levels remained significantly higher and OLDA concentrations significantly lower.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThere was no significant relationship between the number of traumatic event types reported by study subjects and EC/NAE plasma concentrations; these correlated only with PTSD symptom severity.
“However, we found no significant relationship between the number of traumatic event types reported by our study subjects and EC/NAE plasma concentrations, which correlated only with PTSD symptom severity.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataChronically stressed individuals with PTSD showed sustained alterations in EC and NAE plasma concentrations which changed in proportion to PTSD symptom intensity and were seen long after termination of the actual life-threatening situation.
“Our chronically stressed individuals with PTSD showed sustained alterations in EC and NAE plasma concentrations which changed in proportion to PTSD symptom intensity and were seen long after termination of the actual life-threatening situation.”
Quote in the paperSubstantial claimMay combine two claims.
Findingnone givenStudy participants with PTSD had a higher incidence of depression and reported a higher use of antidepressants.
“Study participants with PTSD had a higher incidence of depression and also reported a higher use of antidepressants.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductown dataControls had more years of education than trauma-exposed individuals.
“Trauma-exposed individuals and controls did not differ significantly with respect to age or gender distribution, but controls had more years of education.”
Quote in the paperNot a substantial claimMay combine two claims.
Study design and conductown dataTrauma-exposed individuals and controls did not differ significantly with respect to age or gender distribution.
“Trauma-exposed individuals and controls did not differ significantly with respect to age or gender distribution, but controls had more years of education.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductown dataIndividuals with PTSD reported a higher use of antidepressants than non-trauma-exposed controls.
“Individuals with PTSD reported a higher use of antidepressants than non-trauma-exposed controls.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationPatients with PTSD exhibit high rates of cannabis abuse, which may represent a form of self-medication.
“This line of reasoning is corroborated by the observation that patients with PTSD exhibit high rates of cannabis abuse which may represent a form of self-medication [16]”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [16] JR Cornelius, 2010, PTSD contributes to teen and young adult cannabis use disorders, Addictive Behaviors source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductcitationThe Mini International Neuropsychiatric Interview (MINI) was applied to screen for potential comorbid mental disorders.
“The Mini International Neuropsychiatric Interview (MINI) [25] was applied to screen for potential comorbid mental disorders.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [25] DV Sheehan, 1998, The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10, J Clin Psychiatry
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductown dataWith the exception of antidepressants, medication use was equally distributed between traumatized individuals and those with PTSD.
“With the exception of antidepressives, medication use was equally distributed between traumatized individuals and those with PTSD (Table 1).”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductcitationThe severity of depressive symptoms was assessed with the Hamilton Depression Rating Scale (HAMD).
“In addition, the severity of depressive symptoms was assessed with the Hamilton Depression Rating Scale (HAMD) [26].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [26] M Hamilton, 1960, A rating scale for depression, J Neurol Neurosurg Psychiatry source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenThe HPLC-MS-MS method is linear within the calibration ranges used.
“Our method is linear within these calibration ranges.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductown dataThe lower limit of detection of the method was 0.025 ng/ml for ANA and 0.33 ng/ml for 2-AG.
“The lower limit of detection of the method (defined as a signal/noise ratio >4∶1) was 0.025 ng/ml for ANA and 0.33 ng/ml for 2-AG.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductcitationSomatic symptoms were assessed using a shortened version of Screening for Somatoform Symptoms-7 (SOMS-7).
“Somatic symptoms were assessed using a shortened version of Screening for Somatoform Symptoms-7 (SOMS-7) [23].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [23] W Rief, 2003, A new approach to the assessment of the treatment effects of somatoform disorders, Psychosomatics source
Not checked in the free run.
Classified as probably not a substantial claim. May combine two claims.
Study design and conductcitationThe time interval between blood sampling and centrifugation was kept below 10 min because EC generation in blood samples continues ex vivo.
“The time interval between blood sampling and centrifugation was kept below 10 min because previous experiments have shown that EC generation in blood samples is continued ex vivo [33], [34].”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [33] M Vogeser, 2006, Release of anandamide from blood cells, Clin Chem Lab Med source
Not checked in the free run.
- cites [34] A Schmidt, 2006, Determination of the endocannabinoid anandamide in human plasma by high-performance liquid chromatography, Biomed Chromatogr source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationEC plasma levels in frozen samples remain stable for at least 6 months.
“EC plasma levels in frozen samples have been shown to remain stable for at least 6 months [35].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [35] V Di Marzo, 2009, Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects, Eur J Endocrinol source
Not checked in the free run.
Classified as probably not a substantial claim.
Study design and conductreasoningThe study estimated a sample size of 8 per group to detect significant differences between groups with alpha 0.05 and power 0.80 using ANOVA.
“Based on an alpha value of 0.05 and a power of 0.80 and the comparison of 3 groups (healthy controls, subjects with traumatic experiences but no PTSD, and patients with PTSD) using ANOVA, we estimated a sample size of 8 per group to detect significant differences between groups.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenThe investigators who performed the measurements were blinded for the group assignment of the probes.
“The investigators who performed the measurements were blinded for the group assignment of the probes.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim. May combine two claims.
Study design and conductnone givenPTSD was diagnosed according to DSM-IV criteria by administering the Clinician Administered PTSD Scale (CAPS), which also assesses traumatic events.
“PTSD was diagnosed according to DSM-IV criteria by administering the Clinician Administered PTSD Scale (CAPS), which also assesses traumatic events.”
Quote in the paperSubstantial claimMay combine two claims.
Study design and conductown dataNone of the study participants took steroids, had acute illness or organic disorders such as diabetes, atherosclerotic disease or obesity, had a history of cannabis or other drug abuse or were abusing drugs at the time of evaluation, or had evidence of psychosis.
“None of the study participants took steroids (neither orally nor by inhalation), had acute illness or organic disorders such as diabetes, atherosclerotic disease or obesity (these conditions are known to influence the EC system [20], [22]), had a history of cannabis or other drug abuse or were abusing drugs at the time of evaluation or had evidence of psychosis.”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [20] K Sugamura, 2009, Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages, Circulation source
Not checked in the free run.
- cites [22] M Cote, 2007, Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men, Int J Obes (Lond) source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationEC plasma concentrations are modified by the presence of affective disorders and severe mental illness.
“EC plasma concentrations are also modified by the presence of affective disorders and severe mental illness [7], [8].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [7] MN Hill, 2009, Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress, Psychoneuroendocrinology source
Not checked in the free run.
- cites [8] E Schwarz, 2011, Alterations of primary fatty acid amides in serum of patients with severe mental illness, Frontiers in Bioscience
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationEC and NAE blood concentrations are lower in patients with depression.
“there are a number of recent studies which demonstrated that EC and NAE blood concentrations increase in response to acute stress [7], [10] and that they are higher in individuals who show stress tolerance [10] and lower in patients with depression [18].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [18] MN Hill, 2008, Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report, Pharmacopsychiatry source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationEC and NAE blood concentrations are higher in individuals who show stress tolerance.
“there are a number of recent studies which demonstrated that EC and NAE blood concentrations increase in response to acute stress [7], [10] and that they are higher in individuals who show stress tolerance [10] and lower in patients with depression [18].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [10] A Chouker, 2010, Motion sickness, stress and the endocannabinoid system, PLoS One source
Not checked in the free run.
Classified as probably not a substantial claim.
PremisecitationEC and NAE blood concentrations increase in response to acute stress.
“there are a number of recent studies which demonstrated that EC and NAE blood concentrations increase in response to acute stress [7], [10] and that they are higher in individuals who show stress tolerance [10] and lower in patients with depression [18].”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [7] MN Hill, 2009, Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress, Psychoneuroendocrinology source
Not checked in the free run.
- cites [10] A Chouker, 2010, Motion sickness, stress and the endocannabinoid system, PLoS One source
Not checked in the free run.
Probably not a substantial claim: may not pass S2 (checkable).
InterpretationreasoningThe association between PTSD and plasma EC/NAE changes may have pathophysiological and diagnostic consequences.
“This may have pathophysiological and diagnostic consequences but will need to be reproduced in larger cohorts.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationThe presence of heart disease could have influenced plasma EC concentrations and did not allow demonstration of a direct relationship between PTSD symptoms and plasma EC levels.
“The presence of heart disease, however, could have influenced plasma EC concentrations [20], and this did not allow the demonstration of a direct relationship between PTSD symptoms and plasma EC levels.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [20] K Sugamura, 2009, Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages, Circulation source
Not checked in the free run.
Classified as probably not a substantial claim.
PremisecitationStimulation of EC signaling in patients with PTSD by administration of the synthetic cannabinoid nabilone resulted in an improvement of memory-related PTSD symptoms.
“a recent study demonstrated that a stimulation of EC signaling in patients with PTSD by administration of the synthetic cannabinoid nabilone resulted in an improvement of memory-related PTSD symptoms [17].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [17] GA Fraser, 2009, The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD), CNS neuroscience & therapeutics source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationPhysical stress induced by strenuous exercise during mountaineering or cycling resulted in elevated EC concentrations which returned to baseline after termination of the stressful activity.
“Physical stress in trained and physically fit individuals induced by strenuous exercise during mountaineering or cycling also resulted in elevated EC concentrations which returned to baseline after termination of the stressful activity [37], [38].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [37] M Feuerecker, 2012, Effects of exercise stress on the endocannabinoid system in humans under field conditions, Eur J Appl Physiol source
Not checked in the free run.
- cites [38] E Heyman, 2011, Intense exercise increases circulating endocannabinoid and BDNF levels in humans-Possible implications for reward and depression, Psychoneuroendocrinology source
Not checked in the free run.
May combine two claims.
Interpretationown data2-AG and OLDA may represent more robust indicators of the presence of PTSD.
“This suggests that these two compounds may represent more robust indicators of the presence of PTSD but these assumptions definitively need to be corroborated in larger studies.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationExposure of healthy volunteers to kinetic stress during a parabolic flight experiment gave rise to a significant increase in plasma EC concentrations in stress-tolerant participants, whereas highly stressed individuals showed an absent EC response and a massive activation of the HPA axis.
“Exposure of healthy volunteers to kinetic stress during a parabolic flight experiment gave rise to a significant increase in plasma EC concentrations in stress-tolerant participants, whereas highly stressed individuals showed an absent EC response and a massive activation of the hypothalamic-pituitary-adrenal (HPA) axis [10].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [10] A Chouker, 2010, Motion sickness, stress and the endocannabinoid system, PLoS One source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationStress induced by the Trier Social Stress Test resulted in a significant increase in ANA, PEA and OEA plasma concentrations.
“Stress induced by the Trier Social Stress Test resulted in a significant increase in ANA, PEA and OEA plasma concentrations [30].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [30] A Dlugos, 2012, Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans, Neuropsychopharmacology source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationActivated macrophages and other nuclear blood cells are believed to be the major source of circulating ECs in blood.
“Activated macrophages and other nuclear blood cells are believed to be the major source of circulating ECs in blood [33], [42].”
Quote in the paperNot a substantial claim0 of 2 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationInhibition of EC signaling by CB1 receptor blockade in circulating macrophages is associated with a significant reduction in pro-inflammatory mediators.
“whereas an inhibition of EC signaling by CB1 receptor blockade in circulating macrophages is associated with a significant reduction in pro-inflammatory mediators [20].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [20] K Sugamura, 2009, Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages, Circulation source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThere is evidence of elevated plasma levels of ANA and 2-AG in patients with atherosclerosis and coronary artery disease.
“Although an enhanced EC signaling may have protective and adaptive effects during or after a major stress exposure, there is evidence of elevated plasma levels of ANA and 2-AG in patients with atherosclerosis and coronary artery disease [20], [41]”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [20] K Sugamura, 2009, Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages, Circulation source
Not checked in the free run.
- cites [41] F Weis, 2010, Effect of anaesthesia and cardiopulmonary bypass on blood endocannabinoid concentrations during cardiac surgery, British Journal of Anaesthesia source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationPatients with PTSD often abuse cannabinoids.
“Interestingly, patients with PTSD often abuse cannabinoids [16]”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [16] JR Cornelius, 2010, PTSD contributes to teen and young adult cannabis use disorders, Addictive Behaviors source
Not checked in the free run.
Classified as probably not a substantial claim.
PremisecitationThe lipid response to acute stress is significantly higher in Caucasians than in African-Americans.
“A recent study has shown that the lipid response to acute stress is significantly higher in Caucasians than in African-Americans [30].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [30] A Dlugos, 2012, Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans, Neuropsychopharmacology source
Not checked in the free run.
May combine two claims.
InterpretationreasoningDespite elevated EC and NAE plasma concentrations as part of a stress reaction in PTSD patients, enhanced endocannabinoid signaling might be insufficient to completely restore homeostasis and a further reduction in symptoms by exogenous cannabinoids is possible.
“Thus, despite elevated EC and NAE plasma concentrations as part of a stress reaction in PTSD patients, the enhanced endocannabinoid signaling might be insufficient to completely restore homeostasis and a further reduction in symptoms by exogenous cannabinoids is possible.”
Quote in the paperSubstantial claimMay combine two claims.
InterpretationreasoningChanges in peripheral EC/NAE concentrations may reflect alterations in central EC signaling along with EC/NAE associated behavioral effects.
“These findings suggest that changes in peripheral EC/NAE concentrations may indeed reflect alterations in central EC signaling along with EC/NAE associated behavioral effects.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Study design and conductnone givenAll subjects appeared to be comfortable during blood drawing and were habituated to the procedure from previous medical visits.
“These effects are difficult to control for, but all our subjects appeared to be comfortable during blood drawing and were habituated to the procedure from previous medical visits.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S2 (checkable).
InterpretationreasoningThe finding that PTSD is associated with changes in plasma EC/NAE concentrations may have both pathophysiological and diagnostic consequences for PTSD.
“This finding may have both pathophysiological as well as diagnostic consequences for PTSD but needs to be reproduced in larger and more homogenous study groups.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationAnimal studies have shown that stress reduces brain EC concentrations.
“One should keep in mind, however, that animal studies have also shown that stress reduces brain EC concentrations [44].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [44] MN Hill, 2009, Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis, Neuropsychopharmacology source
Not checked in the free run.
The authors state this as an assumption.
Changes in endocannabinoid signaling might play a role in either the development or persistence of PTSD.
“Given the fact that post-traumatic stress disorder (PTSD) is an anxiety disorder characterized by an inappropriate persistence and uncontrolled retrieval of traumatic memories, it can be assumed that changes in EC signaling might play a role in either the development or persistence of PTSD.”
The paper relies on this without support.
The German control subjects may have a different health status or differences in overall stress exposure compared to other controls.
“as well as individuals of German origin who may have a different health status or differences in the overall stress exposure”
The paper relies on this without support.
The remaining controls (refugees) were exposed to higher stress levels during immigration, which could result in increased plasma lipid signaling.
“They were almost certainly exposed to higher stress levels during immigration which could result in increased plasma lipid signaling, although this possibility is difficult to proof with the questionnaires and instruments used in our study.”
The authors state this as an assumption.
An activated peripheral EC system might play a causal role in the reported increased risk for coronary artery disease and the associated enhanced mortality in patients with PTSD.
“Therefore, an activated peripheral EC system might play a causal role in the reported increased risk for coronary artery disease and the associated enhanced mortality in patients with PTSD [43]. This assumption is corroborated”
The authors state this as an assumption.
Increased EC signaling during acute stress is a protective response to maintain homeostasis and enhance the recovery process.
“The latter two findings may allow speculating that an increased EC signaling during acute stress is a protective response to maintain homeostasis and enhance the recovery process. In line with this assumption”
The authors state this as an assumption.
If depression and the use of antidepressants have an effect on the finding of increased EC/NAE plasma levels in PTSD patients, these confounders may have actually resulted in lower rather than increased plasma concentrations.
“Thus, if depression and the use of antidepressants have an effect on our finding of increased EC/NAE plasma levels in PTSD patients one could assume that these confounders may have actually resulted in lower rather than increased plasma concentrations.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In patients with PTSD or depression, 2-AG plasma levels are lower than in healthy controls.
“In patients with PTSD or depression 2-AG plasma levels have been found to be lower than in healthy controls (Hauer et al., 2013), and in mice lacking the 2-AG synthesising enzyme diacylglycerol lipase anxiety-related behaviour is enhanced (Jenniches et al., 2016;Shonesy et al., 2014).”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Hauer et al., 2013
Reduced circulating 2-AG is found in patients with PTSD.
“Reduced circulating 2-AG has also been found in patients with PTSD (Hill et al., 2013a) (though for the opposite effect, see Hauer et al., 2013).”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Hauer et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Discussion denies a reported traumatic-events correlation
MajorThe Discussion states that traumatic event-type counts had no significant relationship with EC/NAE concentrations. Figure 5 reports a significant relationship between CAPS traumatic event types and OLDA concentration (p = 0.03).
“However, we found no significant relationship between the number of traumatic event types reported by our study subjects and EC/NAE plasma concentrations, which correlated only with PTSD symptom severity.”
“Figure: Figure 5 Correlation between the number of CAPS traumatic event types and OLDA plasma concentrations (r = −0.50, p = 0.03, n = 19).”
Smoker totals differ between tables
MajorTable 1 lists 6, 6 and 4 smokers in the three groups, totaling 16. Table 4 instead classifies only 11 of the same 48 study participants as smokers.
“| Smokers (yes/no) | 6/3 | 6/4 | 4/25 | 0.17 |”
“| EC/NAE (ng/ml) | Cigarette smoking No (n = 37) | Cigarette smoking Yes (n = 11) | Cigarette smoking p |”
Trauma-exposed female count conflicts with Table 1
MajorThe text reports nine females among the 19 trauma-exposed participants, but Table 1 lists three females without PTSD and two with PTSD, for a total of five.
“We assessed 19 individuals (age: 33.2±9.8 years, 9 females) with prior trauma exposure”
“| Sex (f/m) | 3/6 | 2/8 | 17/12 | 0.08 |”
Depression count differs between text and Table 2
MinorThe text says eight trauma-exposed individuals had a current major depressive episode, while Table 2 classifies nine as having depression.
“Eight of the trauma-exposed individuals met the DSM-IV criteria for a current major depressive episode (two subjects from the trauma exposure only group and six individuals with PTSD, p = 0.15, Fisher’s exact test)”
“| EC/NAE | Depression No (n = 10) | Depression Yes (n = 9) | Depression p | Antidepressives No (n = 14) | Antidepressives Yes (n = 5) | Antidepressives p |”
CAPS subscores do not add to the reported total without PTSD
MinorFor trauma-exposed participants without PTSD, the three listed mean CAPS subscores add to 27.4, not the reported mean CAPS score of 24.6. The corresponding PTSD-group subscores do add to that group's reported total.
Reported 24.6 · recomputed 27.4
“| CAPS Scorea | 24.6±24.4 | 94.9±15.4* | 0.0 c | <0.01 | | CAPS – intrusions | 10.6±9.8 | 32.8±5.5 * | 0.0 | <0.01 | | CAPS – avoidance | 8.4±6.5 | 36.2±8.2 * | 0.0 | <0.01 | | CAPS - hyperarousal | 8.4.±10.0 | 25.9±7.6 * | 0.0 | <0.01 |”
CAPS and war-event summaries appear reversed
MinorThe text assigns 8.8±6.9 to CAPS event types and 8.1±2.2 to war- and torture-related events. The subgroup values in Table 1 instead combine to approximately 8.1 for CAPS events and 8.8 for war or torture events.
“Trauma-exposed participants had multiple traumatic experiences with 8.8±6.9 different traumatic event types on the event checklist of the CAPS [21] as well as 8.1±2.2 war- and torture-related events.”
“| War or torture events | 5.2±5.7 | 12.0±6.5 * | 0.44±0.7 c | <0.01 | | CAPS events | 7.7±2.3 | 8.5±2.1 # | 2.7±1.2 c | <0.01 |”
Reported age does not match the subgroup ages
MinorThe reported mean age of the 19 trauma-exposed participants is 33.2 years. Table 1 gives means of 33.6 years for nine participants and 33.8 years for ten, which combine to approximately 33.7 years.
“We assessed 19 individuals (age: 33.2±9.8 years, 9 females) with prior trauma exposure”
“| Agea (y) | 33.6±12.2 | 33.8±7.5 | 33.5±9.3 | 0.96 |”
Listed countries account for six, not seven, excluded participants
MinorThe country counts in the parenthesis add to six, although the passage says seven non-Caucasian individuals were excluded.
Reported 7 · recomputed 6
“excluding non-Caucasian individuals (n = 7) (one each from Sudan, Namibia, Senegal and Nigeria and two from Gambia; two of these individuals were from the control group, 3 were trauma exposed but did not develop PTSD and 2 had PTSD)”
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · see citing works
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139 · see citing works
(1998) · PubMed · Cited by 10,216 · see citing works
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D. V., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,882 · see citing works
The development of a Clinician-Administered PTSD Scale
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995) · Journal of Traumatic Stress · doi:10.1002/jts.2490080106 · Cited by 5,024 · see citing works
Lecrubier, Y., Sheehan, D., Weiller, E., Amorim, P., Bonora, I., Sheehan, K. H., Janavs, J., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83296-8 · Cited by 3,513 · see citing works
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · see citing works
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · see citing works
The endocannabinoid system: a general view and latest additions
PETROCELLIS, L. D., Cascio, M. G., & Marzo, V. D. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705666 · Cited by 473 · see citing works
Boscarino, J. A. (2008) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31817bccaf · Cited by 434 · see citing works
Heyman, E., Gamelin, F.-X., Goekint, M., Piscitelli, F., Roelands, B., Leclair, E., Di Marzo, V., & Meeusen, R. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.09.017 · Cited by 427 · see citing works
Côté, M., Matias, I., Lemieux, I., Petrosino, S., Alméras, N., Després, J., & Marzo, V. D. (2007) · International Journal of Obesity · doi:10.1038/sj.ijo.0803539 · Cited by 382 · see citing works
Endogenous cannabinoid signaling is essential for stress adaptation
Hill, M. N., McLaughlin, R. J., Bingham, B., Shrestha, L., Lee, T. T. Y., Gray, J. M., Hillard, C. J., Gorzalka, B. B., & Viau, V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914661107 · Cited by 349 · see citing works
Hill, M. N., Miller, G. E., Carrier, E. J., Gorzalka, B. B., & Hillard, C. J. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.03.013 · Cited by 328 · see citing works
Hill, M. N., McLaughlin, R. J., Morrish, A. C., Viau, V., Floresco, S. B., Hillard, C. J., & Gorzalka, B. B. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.114 · Cited by 304 · see citing works
Campolongo, P., Roozendaal, B., Trezza, V., Hauer, D., Schelling, G., McGaugh, J. L., & Cuomo, V. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900835106 · Cited by 294 · see citing works
Self-citationSerum Endocannabinoid Content is Altered in Females with Depressive Disorders: A Preliminary Report
Hill, M., Miller, G., Ho, W.-S., Gorzalka, B., & Hillard, C. (2008) · Pharmacopsychiatry · doi:10.1055/s-2007-993211 · Cited by 292 · see citing works
Fraser, G. A. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00071.x · Cited by 283 · cited 2× · see citing works
“Interestingly, patients with PTSD often abuse cannabinoids [16] and the use of the synthetic cannabinoid nabilone resulted in an improvement of symptoms [17].”
BackgroundResultStoll, C., Kapfhammer, H. P., Rothenhäusler, H. B., Haller, M., Briegel, J., Schmidt, M., Krauseneck, T., Durst, K., & Schelling, G. (1999) · Intensive Care Medicine · doi:10.1007/s001340050932 · Cited by 278 · cited 1× · see citing works
“PTSD was excluded in these individuals by using the Post-Traumatic Stress Symptom 10 Questionnaire (PTSS-10) [27].”
MethodSelf-citationAcute stress increases circulating anandamide and other N-acylethanolamines in healthy humans
Dlugos, A., Childs, E., Stuhr, K. L., Hillard, C. J., & de Wit, H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.100 · Cited by 248 · see citing works
Sugamura, K., Sugiyama, S., Nozaki, T., Matsuzawa, Y., Izumiya, Y., Miyata, K., Nakayama, M., Kaikita, K., Obata, T., Takeya, M., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.811992 · Cited by 196 · see citing works
Moreira, F. A., & Wotjak, C. T. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_16 · Cited by 177 · see citing works
A New Approach to the Assessment of the Treatment Effects of Somatoform Disorders
Rief, W., & Hiller, W. (2003) · Psychosomatics · doi:10.1176/appi.psy.44.6.492 · Cited by 171 · see citing works
Patel, S., & Hillard, C. J. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06266.x · Cited by 162 · see citing works
Motion Sickness, Stress and the Endocannabinoid System
Choukèr, A., Kaufmann, I., Kreth, S., Hauer, D., Feuerecker, M., Thieme, D., Vogeser, M., Thiel, M., & Schelling, G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010752 · Cited by 140 · see citing works
Self-citationAtsak, P., Hauer, D., Campolongo, P., Schelling, G., McGaugh, J. L., & Roozendaal, B. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200742109 · Cited by 140 · see citing works
Self-citationThe emerging role of the endocannabinoid system in cardiovascular disease
Pacher, P., & Steffens, S. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0145-8 · Cited by 139 · see citing works
Fat-induced satiety factor oleoylethanolamide enhances memory consolidation
Campolongo, P., Roozendaal, B., Trezza, V., Cuomo, V., Astarita, G., Fu, J., McGaugh, J. L., & Piomelli, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903038106 · Cited by 133 · see citing works
Self-citationGanon-Elazar, E., & Akirav, I. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.204 · Cited by 120 · see citing works
Marzo, V. D., Verrijken, A., Hakkarainen, A., Petrosino, S., Mertens, I. L., Lundbom, N. M. I., Piscitelli, F., Westerbacka, J., Soro‐Paavonen, A., Matias, I., et al. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0643 · Cited by 117 · see citing works
Balvers, M. G. J., Verhoeckx, K. C. M., & Witkamp, R. F. (2009) · Journal of Chromatography B · doi:10.1016/j.jchromb.2009.04.010 · Cited by 105 · see citing works
Fanelli, F., Lallo, V. D. D., Belluomo, I., IASIO, R. D., Baccini, M., Casadio, E., Gasparini, D. I., Colavita, M., Gambineri, A., Grossi, G., et al. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m021378 · Cited by 105 · see citing works
Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis
Filippo, M. D., Pini, L. A., Pelliccioli, G. P., Calabresi, P., & Sarchielli, P. (2008) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.139071 · Cited by 89 · see citing works
The Endocannabinoid System in Peripheral Lymphocytes as a Mirror of Neuroinflammatory Diseases
Centonze, D., Battistini, L., & Maccarrone, M. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208785740018 · Cited by 86 · see citing works
PTSD contributes to teen and young adult cannabis use disorders
Cornelius, J. R., Kirisci, L., Reynolds, M., Clark, D. B., Hayes, J., & Tarter, R. (2010) · Addictive Behaviors · doi:10.1016/j.addbeh.2009.09.007 · Cited by 80 · cited 2× · see citing works
“Interestingly, patients with PTSD often abuse cannabinoids [16] and the use of the synthetic cannabinoid nabilone resulted in an improvement of symptoms [17].”
BackgroundResultEffects of exercise stress on the endocannabinoid system in humans under field conditions
Feuerecker, M., Hauer, D., Tóth, R., Demetz, F., Hölzl, J., Thiel, M., Kaufmann, I., Schelling, G., & Choukèr, A. (2011) · European Journal of Applied Physiology · doi:10.1007/s00421-011-2237-0 · Cited by 79 · see citing works
Self-citationRelease of anandamide from blood cells
Vogeser, M., Hauer, D., Azad, S. C., Huber, E., Storr, M., & Schelling, G. (2006) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2006.065 · Cited by 77 · see citing works
Self-citationInteraction between cytokines, cannabinoids and the nervous system
Jean-Gilles, L., Gran, B., & Constantinescu, C. S. (2010) · Immunobiology · doi:10.1016/j.imbio.2009.12.006 · Cited by 72 · see citing works
Maccarrone, M., Cartoni, A., Parolaro, D., Margonelli, A., Massi, P., Bari, M., Battista, N., & Finazzi‐Agrò, A. (2002) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2002.1164 · Cited by 67 · see citing works
Pitfalls in measuring the endocannabinoid 2-arachidonoyl glycerol in biological samples
Vogeser, M., & Schelling, G. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2007.197 · Cited by 51 · see citing works
Self-citationSchmidt, A., Brune, K., & Hinz, B. (2005) · Biomedical Chromatography · doi:10.1002/bmc.568 · Cited by 39 · see citing works
Weis, F. C., Beiras-Fernandez, A., Hauer, D., Hornuß, C., Sodian, R., Kreth, S., Briegel, J., & Schelling, G. (2010) · British Journal of Anaesthesia · doi:10.1093/bja/aeq117 · Cited by 36 · see citing works
Self-citationThe Endocannabinoid System in the Cancer Therapy: An Overview
Grimaldi, C., & Capasso, A. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795471374 · Cited by 33 · see citing works
Hauer, D., Weis, F., Campolongo, P., Schopp, M., Beiras-Fernandez, A., Strewe, C., Giehl, M., Toth, R., Kilger, E., & Schelling, G. (2012) · Reviews in the Neurosciences · doi:10.1515/revneuro-2012-0058 · Cited by 33 · cited 2× · see citing works
“Depression is known to be associated with lower EC plasma levels [7,39] whereas our individuals with PTSD showed increased concentrations.”
BackgroundSelf-citationEx Vivo Imaging of Fatty Acid Amide Hydrolase Activity and Its Inhibition in the Mouse Brain
Glaser, S. T., Gatley, S. J., & Gifford, A. N. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.094748 · Cited by 26 · see citing works
Effects of single swim stress on changes in TRPV1-mediated plasticity in the amygdala
Kulisch, C., & Albrecht, D. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.09.003 · Cited by 24 · see citing works
Alterations of primary fatty acid amides in serum of patients with severe mental illness
Bahn, S. (2010) · Frontiers in Bioscience-Elite · doi:10.2741/e246 · Cited by 15 · see citing works
Flagged first, then by citations
1 of the 48 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- D Hauer, 2008, Traumatic Memories in Surgical Patients Are a Significant Predictor of Endocannabinoid Activity, Anesthesiology, 109, A1015
- Schauer M, Neuner F, Elbert T (2011): Vivo Checklist for War, Detention, and Torture Events; in : Narrative Exposure Therapy (NET). A Short-Term Intervention for Traumatic Stress Disorders. Cambridge/Göttingen, Hogrefe & Huber Publishers, 77–79.
Cited by
Sorted by citations
Izquierdo, I., Furini, C. R. G., & Myskiw, J. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00018.2015 · Cited by 453 · see citing works
Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?
Hillard, C. J. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.130 · Cited by 449 · see citing works
Iannotti, F. A., Marzo, V. D., & Petrosino, S. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.02.002 · Cited by 357 · see citing works
Hill, M. N., Bierer, L. M., Makotkine, I., Golier, J. A., Galea, S., McEwen, B. S., Hillard, C. J., & Yehuda, R. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.08.004 · Cited by 256 · see citing works
Hill, M. N., Campolongo, P., Yehuda, R., & Patel, S. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.162 · Cited by 239 · see citing works
Self-citationSartori, S. B., & Singewald, N. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107402 · Cited by 236 · see citing works
The endocannabinoid system as a target for novel anxiolytic drugs
Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.033 · Cited by 233 · see citing works
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201 · see citing works
Palmitoylethanolamide: A Natural Compound for Health Management
Clayton, P., Hill, M., Bogoda, N. O., Subah, S., & Venkatesh, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105305 · Cited by 145 · see citing works
The endocannabinoid system: An emotional buffer in the modulation of memory function
Morena, M., & Campolongo, P. (2014) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.12.010 · Cited by 143 · see citing works
Self-citationMcLaughlin, R. J., Hill, M. N., & Gorzalka, B. B. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.02.006 · Cited by 130 · see citing works
Stress Related Shift Toward Inflammaging in Cosmonauts After Long-Duration Space Flight
Buchheim, J., Matzel, S., Петровна, Р. М., Vassilieva, G. Y., Ponomarev, S. A., Ничипорук, И. А., Hoerl, M., Moser, D., Biere, K., Feuerecker, M., et al. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00085 · Cited by 119 · see citing works
Self-citationHill, M. N., & Patel, S. (2013) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-3-19 · Cited by 117 · see citing works
Endocannabinoid concentrations in hair are associated with PTSD symptom severity
Wilker, S., Pfeiffer, A., Elbert, T. R., Ovuga, E., Karabatsiakis, A., Krumbholz, A., Thieme, D., Schelling, G., & Kolassa, I. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.02.010 · Cited by 116 · see citing works
Self-citationCannabinoid Regulation of Fear and Anxiety: an Update
Papagianni, E. P., & Stevenson, C. W. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1026-z · Cited by 100 · see citing works
Sayd, A., Antón, M., Alén, F., Caso, J. R., Pavon, J., Leza, J. C., de Fonseca, F. R., García‐Bueno, B., & Orío, L. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu111 · Cited by 99 · see citing works
Vascular targets for cannabinoids: animal and human studies
Stanley, C. P., & O’Sullivan, S. E. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12560 · Cited by 99 · see citing works
de Bitencourt, R. M., & Takahashi, R. N. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00502 · Cited by 98 · see citing works
Wolf, O. T., Atsak, P., de Quervain, D. J. ‐., Roozendaal, B., & Wingenfeld, K. (2015) · Journal of Neuroendocrinology · doi:10.1111/jne.12353 · Cited by 97 · see citing works
Self-citationStern, C. A. J., da Silva, T. R., Raymundi, A. M., de Souza, C. P., Sato, V., Kato, L., Guimarães, F. S., Andreatini, R., Takahashi, R. N., & Bertoglio, L. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.024 · Cited by 96 · see citing works
Schaefer, C., Enning, F., Mueller, J. K., Bumb, J. M., Rohleder, C., Odorfer, T. M., Klosterkötter, J., Hellmich, M., Koethe, D., Schmahl, C., et al. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0470-8 · Cited by 92 · see citing works
Oleoylethanolamide, Neuroinflammation, and Alcohol Abuse
Orío, L., Alén, F., Pavón, F. J., Serrano, A., & García‐Bueno, B. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00490 · Cited by 90 · see citing works
Genetics of glucocorticoid regulation and posttraumatic stress disorder -what do we know?
Castro-Vale, I., van Rossum, E. F. C., Machado, J. C., Mota-Cardoso, R., & Carvalho, D. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.02.005 · Cited by 85 · see citing works
Atsak, P., Hauer, D., Campolongo, P., Schelling, G., Fornari, R. V., & Roozendaal, B. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.334 · Cited by 85 · see citing works
Self-citationTrezza, V., & Campolongo, P. (2013) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2013.00100 · Cited by 84 · see citing works
Self-citationThe endocannabinoid system in mental disorders: Evidence from human brain studies
Ibarra‐Lecue, I., Pilar-Cuéllar, F., Muguruza, C., Florensa-Zanuy, E., Díaz, Á., Urigüen, L., Castro, E., Pazos, Á., & Callado, L. F. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.07.009 · Cited by 80 · see citing works
Short overview on metabolomic approach and redox changes in psychiatric disorders
Erjavec, G. N., Konjevod, M., Perković, M. N., Štrac, D. Š., Tudor, L., Barbas, C., Grune, T., Žarković, N., & Pivac, N. (2017) · Redox Biology · doi:10.1016/j.redox.2017.09.002 · Cited by 79 · see citing works
Stern, C. A. J., Gazarini, L., Vanvossen, A. C., Zuardi, A. W., Galve‐Roperh, I., Guimarães, F. S., Takahashi, R. N., & Bertoglio, L. J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.02.001 · Cited by 78 · see citing works
Bedse, G., Hill, M. N., & Patel, S. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.01.015 · Cited by 75 · see citing works
Berardi, A., Schelling, G., & Campolongo, P. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.024 · Cited by 75 · see citing works
Self-citationEndocannabinoids and Mental Disorders
Rubino, T., Zamberletti, E., & Parolaro, D. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_9 · Cited by 71 · see citing works
Raut, S. B., Marathe, P. A., van Eijk, L., Eri, R. D., Ravindran, M., Benedek, D. M., Ursano, R. J., Canales, J. J., & Johnson, L. R. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108195 · Cited by 71 · see citing works
Jin, P., Yu, H.-L., Tian-Lan, Zhang, F., & Quan, Z. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.04.001 · Cited by 68 · see citing works
Chronic treatment with URB597 ameliorates post-stress symptoms in a rat model of PTSD
Fidelman, S., Zer‐Aviv, T. M., Lange, R., Hillard, C. J., & Akirav, I. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.02.004 · Cited by 67 · see citing works
deRoon‐Cassini, T. A., Bergner, C., Chesney, S. A., Schumann, N. R., Lee, T. S., Brasel, K. J., & Hillard, C. J. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01808-1 · Cited by 65 · see citing works
Psychobiological Responses to Aerobic Exercise in Individuals With Posttraumatic Stress Disorder
Crombie, K. M., Brellenthin, A. G., Hillard, C. J., & Koltyn, K. F. (2018) · Journal of Traumatic Stress · doi:10.1002/jts.22253 · Cited by 65 · see citing works
Ney, L. J., Matthews, A. J., Bruno, R., & Felmingham, K. L. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.07.006 · Cited by 65 · see citing works
Animal models of post-traumatic stress disorder and novel treatment targets
Aspesi, D., & Pinna, G. (2019) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000467 · Cited by 65 · see citing works
Bioactive lipids as modulators of immunity, inflammation and emotions
Chiurchiù, V., & Maccarrone, M. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.06.005 · Cited by 64 · see citing works
Endocannabinoids and the Cardiovascular System in Health and Disease
O’Sullivan, S. E. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_14 · Cited by 64 · see citing works
Targeting the endocannabinoid system to treat anxiety-related disorders
Korem, N., Zer‐Aviv, T. M., Ganon-Elazar, E., Abush, H., & Akirav, I. (2015) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2015-0058 · Cited by 64 · see citing works
Crombie, K. M., Leitzelar, B. N., Brellenthin, A. G., Hillard, C. J., & Koltyn, K. F. (2019) · Biological Psychology · doi:10.1016/j.biopsycho.2019.04.002 · Cited by 63 · see citing works
Dopamine, endocannabinoids and their interaction in fear extinction and negative affect in PTSD
Ney, L. J., Akhurst, J., Bruno, R., Laing, P. A. F., Matthews, A. J., & Felmingham, K. L. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110118 · Cited by 61 · see citing works
Therapeutic Challenges of Post-traumatic Stress Disorder: Focus on the Dopaminergic System
Torrisi, S. A., Leggio, G. M., Drago, F., & Salomone, S. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00404 · Cited by 59 · see citing works
Gao, W., Walther, A., Wekenborg, M., Penz, M. S., & Kirschbaum, C. (2020) · Talanta · doi:10.1016/j.talanta.2020.121006 · Cited by 56 · see citing works
Ney, L. J., Felmingham, K. L., Bruno, R., Matthews, A. J., & Nichols, D. S. (2020) · Journal of Chromatography B · doi:10.1016/j.jchromb.2020.122252 · Cited by 56 · see citing works
Metabolite profiling in posttraumatic stress disorder
Karabatsiakis, A., Hamuni, G., Wilker, S., Kolassa, S., Renu, D., Kadereit, S., Schauer, M., Hennessy, T., & Kolassa, I. (2015) · Journal of Molecular Psychiatry · doi:10.1186/s40303-015-0007-3 · Cited by 52 · see citing works
Self-citationStern, C. A. J., de Carvalho, C. R., Bertoglio, L. J., & Takahashi, R. N. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.07.018 · Cited by 52 · see citing works
Yi, B., Ничипорук, И. А., Nicolas, M., Schneider, S., Feuerecker, M., Vassilieva, G. Y., Thieme, D., Schelling, G., & Choukèr, A. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.01.004 · Cited by 51 · see citing works
Self-citationThieme, U., Schelling, G., Hauer, D., Greif, R. T., Dame, T., Laubender, R. P., Bernhard, W. R., Thieme, D., Campolongo, P., & Theiler, L. G. (2013) · Drug Testing and Analysis · doi:10.1002/dta.1561 · Cited by 50 · see citing works
Self-citationHauer, D., Kaufmann, I., Strewe, C., Briegel, I., Campolongo, P., & Schelling, G. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.10.003 · Cited by 49 · see citing works
Self-citationNia, A. B., Bender, R. L., & Harpaz‐Rotem, I. (2019) · Chronic Stress · doi:10.1177/2470547019864096 · Cited by 47 · see citing works
The endocannabinoidome in neuropsychiatry: Opportunities and potential risks
Morris, G., Walder, K. R., Kloiber, S. M., Amminger, G. P., Berk, M., Bortolasci, C. C., Maes, M. H. J., Puri, B. K., & Carvalho, A. F. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105729 · Cited by 47 · see citing works
Abnormalities in neuroendocrine stress response in psychosis: the role of endocannabinoids
Appiah‐Kusi, E., Leyden, E., Parmar, S. R., Mondelli, V., McGuire, P. K., & Bhattacharyya, S. (2015) · Psychological Medicine · doi:10.1017/s0033291715001786 · Cited by 45 · see citing works
Endocannabinoids and Acute Pain Following Total Knee Arthroplasty
Azim, S., Nicholson, J., Rebecchi, M., Galbavy, W., Feng, T., Reinsel, R., Volkow, N., Benveniste, H., & Kaczocha, M. (2015) · Pain · doi:10.1097/01.j.pain.0000460315.80981.59 · Cited by 37 · see citing works
Köse, S., Aerts‐Kaya, F., Köprü, Ç. Z., Nemutlu, E., Kuşkonmaz, B., Karaosmanoğlu, B., Taşkıran, E. Z., Altun, B., Uçkan, D., & Korkusuz, P. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.09.009 · Cited by 44 · see citing works
Patsenker, E., Sachse, P., Chicca, A., Gachet, M. S., Schneider, V., Mattsson, J., Lanz, C., Worni, M., Gottardi, A. D., Semmo, M., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16047057 · Cited by 44 · see citing works
Antonucci, N., Cirillo, A., & Siniscalco, D. (2015) · Case Reports in Psychiatry · doi:10.1155/2015/325061 · Cited by 44 · see citing works
Altered hair endocannabinoid levels in mothers with childhood maltreatment and their newborns
Koenig, A. M., Gao, W., Umlauft, M., Schury, K., Reister, F., Kirschbaum, C., Karabatsiakis, A., & Kolassa, I. (2018) · Biological Psychology · doi:10.1016/j.biopsycho.2018.03.006 · Cited by 42 · see citing works
Self-citationGowatch, L. C., Evanski, J. M., Ely, S. L., Zundel, C. G., Bhogal, A., Carpenter, C., Shampine, M. M., O’Mara, E., Mazurka, R., Barcelona, J., et al. (2024) · Cannabis and Cannabinoid Research · doi:10.1089/can.2023.0246 · Cited by 39 · see citing works
Acquaro, V. R., Gómez‐Ríos, G. A., Tascón, M., Queiroz, M. E. C., & Pawliszyn, J. B. (2019) · Analytica Chimica Acta · doi:10.1016/j.aca.2019.09.002 · Cited by 39 · see citing works
Papini, S., Sullivan, G. M., Hien, D. A., Shvil, E., & Neria, Y. (2014) · Biological Psychology · doi:10.1016/j.biopsycho.2014.10.010 · Cited by 37 · see citing works
Yu, H.-L., Lian-ping, S., Li, M., & Quan, Z. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.03.019 · Cited by 36 · see citing works
Giacobbe, J., Marrocu, A., Benedetto, M. G. D., Pariante, C. M., & Borsini, A. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.12.024 · Cited by 35 · see citing works
Circulating endocannabinoids and affect regulation in human subjects
Coccaro, E. F., Hill, M. N., Robinson, L., & Lee, R. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.03.009 · Cited by 34 · see citing works
Aisenberg, N., Serova, L. I., Sabban, E. L., & Akirav, I. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.06.006 · Cited by 33 · see citing works
Shoshan, N., & Akirav, I. (2017) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2017.08.004 · Cited by 32 · see citing works
Role of palmitoylethanolamide (PEA) in depression: Translational evidence
Gregorio, D. D., Manchia, M., Carpiniello, B., Valtorta, F., Nobile, M., Gobbi, G., & Comai, S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.10.117 · Cited by 32 · see citing works
Behnke, A., Gumpp, A. M., Rojas, R., Sänger, T., Lutz‐Bonengel, S., Moser, D., Schelling, G., Krumbholz, A., & Kolassa, I. (2022) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2070666 · Cited by 30 · see citing works
Self-citationCastillo-Peinado, L. S., López-Bascón, M. A., Mena-Bravo, A., de Castro, M. D. L., & Priego‐Capote, F. (2018) · Talanta · doi:10.1016/j.talanta.2018.09.088 · Cited by 30 · see citing works
Xue, F., Xue, S., Liu, L., Sang, H., Ma, Q., Tan, Q., Wang, H., Zhou, C., & Peng, Z. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.03.018 · Cited by 30 · see citing works
Translation of animal endocannabinoid models of PTSD mechanisms to humans: Where to next?
Ney, L. J., Crombie, K. M., Mayo, L. M., Felmingham, K. L., Bowser, T. A., & Matthews, A. J. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.11.040 · Cited by 30 · see citing works
Jennings, E. M., Okine, B. N., Olango, W. M., Roche, M., & Finn, D. P. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.05.008 · Cited by 29 · see citing works
Walther, A., Kirschbaum, C., Wehrli, S., Rothe, N., Penz, M. S., Wekenborg, M., & Gao, W. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110658 · Cited by 29 · see citing works
Circulating endocannabinoids and psychological outcomes in women with PTSD
Botsford, C., Brellenthin, A. G., Cisler, J. M., Hillard, C. J., Koltyn, K. F., & Crombie, K. M. (2022) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2022.102656 · Cited by 29 · see citing works
Huguenard, C. J. C., Cseresznye, A., Evans, J. E., Oberlin, S., Langlois, H., Ferguson, S., Darcey, T. S., Nkiliza, A., Dretsch, M. N., MULLAN, M. J., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00012 · Cited by 28 · see citing works
Vecchiarelli, H. A., Morena, M., Keenan, C. M., Chiang, V., Tan, K., Qiao, M., Leitl, K. D., Santori, A., Pittman, Q. J., Sharkey, K. A., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00939-7 · Cited by 28 · see citing works
A review of the effects of acute and chronic cannabinoid exposure on the stress response
Glodosky, N. C., Cuttler, C., & McLaughlin, R. J. (2021) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2021.100945 · Cited by 28 · see citing works
Bouter, Y., Brzózka, M. M., Ryguła, R., Pahlisch, F., Boost, C., Leweke, F. M., Havemann‐Reinecke, U., & Rohleder, C. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2019.0041 · Cited by 26 · see citing works
Fattore, L., Piva, A., Zanda, M. T., Fumagalli, G. F., & Chiamulera, C. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4793-4 · Cited by 26 · see citing works
Could a blood test for PTSD and depression be on the horizon?
Aspesi, D., & Pinna, G. (2018) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1544894 · Cited by 26 · see citing works
On making (and turning adaptive to) maladaptive aversive memories in laboratory rodents
Gazarini, L., Stern, C. A. J., & Bertoglio, L. J. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105101 · Cited by 25 · see citing works
Bersani, G., Pacitti, F., Iannitelli, A., Caroti, E., Quartini, A., Xenos, D., Marconi, M., Cuoco, V., Bigio, B., Bowles, N. P., et al. (2021) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2779 · Cited by 24 · see citing works
Strewe, C., Thieme, D., Dangoisse, C., Fiedel, B., van den Berg, F., Bauer, H., Salam, A. P., Gössmann-Lang, P., Campolongo, P., Moser, D., et al. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01647 · Cited by 24 · see citing works
Self-citationCannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review
Dammann, I., Rohleder, C., & Leweke, F. M. (2024) · Pharmacopsychiatry · doi:10.1055/a-2228-6118 · Cited by 23 · see citing works
Intra-individual stability of hair endocannabinoid and N-acylethanolamine concentrations
Gao, W., Schmidt, K., Enge, S., & Kirschbaum, C. (2021) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2021.105395 · Cited by 22 · see citing works
Parksepp, M., Haring, L., Kilk, K., Koch, K., Uppin, K., Kangro, R., Zilmer, M., & Vasar, E. (2022) · Biomedicines · doi:10.3390/biomedicines10020243 · Cited by 22 · see citing works
Bennett, M. R., Arnold, J. C., Hatton, S. N., & Lagopoulos, J. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.11.029 · Cited by 22 · see citing works
Atsak, P., Morena, M., Schoenmaker, C., Tabak, E., Oomen, C. A., Jamil, S., Hill, M. N., & Roozendaal, B. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.02.021 · Cited by 22 · see citing works
Self-citationTagliamonte, S., Gill, C. I. R., Pourshahidi, L. K., Slevin, M. M., Price, R. K., Ferracane, R., Lawther, R., O’Connor, G., & Vitaglione, P. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02398-8 · Cited by 21 · see citing works
Akimov, M., Gamisonia, A. M., Dudina, P. V., Gretskaya, N. M., Gaydaryova, A. A., Kuznetsov, A. S., Зинченко, Г. Н., & Безуглов, В. В. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020622 · Cited by 20 · see citing works
Cannabis use selectively modulates circulating biomarkers in the blood of schizophrenia patients
Ibarra‐Lecue, I., Unzueta‐Larrinaga, P., Barrena-Barbadillo, R., Villate, A., Horrillo, I., Mendivil, B., Landabaso, M. A., Meana, J. J., Etxebarría, N., Callado, L. F., et al. (2022) · Addiction Biology · doi:10.1111/adb.13233 · Cited by 20 · see citing works
Provensi, G., Fabbri, R., Munari, L., Costa, A., Baldi, E., Bucherelli, C., Blandina, P., & Passani, M. B. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw110 · Cited by 20 · see citing works
The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review
Davis, M. P., Behm, B., Mehta, Z. Y., & Fernandez, C. (2019) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909119850807 · Cited by 19 · see citing works
Ross, J. A., & Bockstaele, E. J. V. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14714 · Cited by 19 · see citing works
Leen, N. A., de Weijer, A. D., van Rooij, S. J. H., Kennis, M., Baas, J. M. P., & Geuze, E. (2022) · Chronic Stress · doi:10.1177/24705470221107290 · Cited by 18 · see citing works
Potential Utility of Cannabidiol in Stress-Related Disorders
Lookfong, N. A., Raup‐Konsavage, W. M., & Silberman, Y. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0130 · Cited by 18 · see citing works
Barba, S. V., Kirschbaum, C., & Gao, W. (2023) · Biological Psychology · doi:10.1016/j.biopsycho.2023.108541 · Cited by 18 · see citing works
Novel Pharmacological Targets of Post-Traumatic Stress Disorders
Marazziti, D., Carmassi, C., Cappellato, G., Chiarantini, I., Massoni, L., Mucci, F., Arone, A., Violi, M., Palermo, S., Iorio, G. D., et al. (2023) · Life · doi:10.3390/life13081731 · Cited by 18 · see citing works
Association of endocannabinoids with pain in endometriosis
Andrieu, T., Chicca, A., Pellegata, D., Bersinger, N. A., Imboden, S., Nirgianakis, K., Gertsch, J., & Mueller, M. D. (2021) · Pain · doi:10.1097/j.pain.0000000000002333 · Cited by 18 · see citing works
- Authors
- Hauer, D., Schelling, G., Gola, H., Campolongo, P., Morath, J., Roozendaal, B., Hamuni, G., Karabatsiakis, A., Atsak, P., Vogeser, M., & Kolassa, I.-T.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- University of Konstanz (DE)
- Sapienza University of Rome (IT)
- Radboud University Nijmegen (NL)
- Universität Ulm (DE)
- Corresponding author
- Schelling, Gustav
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-07
- Volume
- 8
- Issue
- 5
- Pages
- e62741
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3647054
- OpenAlex
- W2008780699
- Semantic Scholar
- 8a8ef8246cc5a9190426ce1cd930743c7f73881e
- Cited by
- 200
- References
- 48
- Citations by year
- 2026: 6 · 2025: 17 · 2024: 12 · 2023: 19 · 2022: 17 · 2021: 16 · 2020: 15 · 2019: 18 · 2018: 17 · 2017: 15 · 2016: 11 · 2015: 18 · 2014: 6 · 2013: 12
- FWCI
- 11.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KOPS (University of Konstanz) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Universitätsbibliothek der LMU
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- post-traumatic stress disorder, endocannabinoids, anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, oleoylethanolamide, plasma concentration, trauma exposure, anxiety, traumatic memory, stress response
- MeSH terms
- Adult, Amides, Female, Humans, Hydrocortisone, Male, Stress Disorders, Post-Traumatic, Stress, Psychological, Torture, Warfare, Cohort Studies, Case-Control Studies, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-09.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-09.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review